Institute for Protein Design
Facts
- HQ
- University of Washington School of Medicine
- Sectors
- Biotechnology, Biopharma, Drug discovery, Protein engineering
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Anindya Roy Co-founds Lila Biologics to Advance AI-Driven Medical Therapies After Journey from Rural India to UW Lab
Anindya Roy, who moved from rural India to the U.S. in 2008 with limited resources, has co-founded Lila Biologics in 2023 to develop innovative medical therapies using AI-powered protein design. His journey from humble beginnings to a postdoctoral fellowship under Nobel laureate David Baker exemplifies determination and scientific innovation.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
Seattle Startups Yoodli and A-Alpha Bio Appoint New C-Suite Execs, TiE Seattle Names Siddhartha Srinivasa as President
Seattle startups Yoodli, A-Alpha Bio, and MoxiWorks have added senior executives, including Andy Larson as Yoodli's CFO and Troy Lionberger as A-Alpha Bio's chief business officer, while TiE Seattle appointed Siddhartha Srinivasa as president. These moves highlight growth and leadership shifts in the Seattle tech sector, with companies focusing on AI, biotech, and robotics.
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
Lila Biologics, Nobel Laureate’s Startup, Partners with Eli Lilly to Develop AI-Based Tumor Therapies
Lila Biologics, a startup from Nobel Laureate David Baker's University of Washington lab, is collaborating with Eli Lilly to develop AI-powered tumor-targeted therapies, aiming to deliver a candidate protein for clinical trials within six months. The startup utilizes AI and machine learning platforms to create therapeutic proteins for targeted radiotherapy and long-acting injectable drugs.
Seattle Lags Behind San Francisco in Top AI Startup Funding Deals in 2025 Despite Strong Talent Pool
Despite Seattle's strong AI talent and institutions, no Seattle-area startups rank among the top 100 AI funding deals in 2025, as investors favor San Francisco-based companies for large funding rounds. The city has potential but currently lacks a defining AI startup comparable to Anthropic or OpenAI.
Seattle Startup Summit Highlights City's AI Strengths and Need for More Entrepreneurial Energy
At the inaugural Seattle Startup Summit, leaders like Statsig CEO Vijaye Raji and Acquired podcast co-host Ben Gilbert highlighted Seattle's strong AI ecosystem, anchored by tech giants Amazon and Microsoft, and specialization in biotech and disease research. Despite this, they noted the city could benefit from cultivating a more vibrant entrepreneurial culture to maximize its potential in AI innovation.
Seattle Startup Arzeda Raises $38M to Advance Protein Design for Industrial and Agricultural Applications
Seattle-based protein design startup Arzeda raised $38 million in its latest funding round, bringing total investments to $86 million to develop enzymes for industrial and agricultural uses. The company works with major partners like Unilever, BP, and Gore-Tex makers, and was the first spinout from the University of Washington's Institute for Protein Design.
Pack Ventures Seeks $30M for Second Fund to Invest in University of Washington-Linked Startups
Pack Ventures, a venture capital fund focused on University of Washington-linked startups, raised $5 million for its first fund and is now aiming to raise $30 million for a second fund to expand its investments. The firm has established a preferred partnership with UW and co-invests with other Seattle VCs in companies across life sciences, software, and healthcare sectors.
Seattle Tech Week Returns July 29 with Focus on AI Innovation and Healthcare, Backed by Madrona Ventures
Seattle Tech Week returns starting July 29, featuring panel discussions and networking events centered on AI innovations and healthcare advancements in the Seattle tech ecosystem, coordinated by Madrona Ventures and other sponsors. The event highlights Seattle’s strong presence in AI and biotech sectors with sessions led by local tech giants, researchers, and startups.
Cyrus Biotechnology Launches Levitate Bio to Broaden Access to Rosetta Drug Development Software
Seattle startup Cyrus Biotechnology has spun out a new for-profit company, Levitate Bio, owned by the Rosetta Commons Foundation, to expand access to its versatile drug development software platform, Rosetta. Levitate Bio, led by CEO Sam DeLuca and executive VP Karen Khar, aims to support innovation across drug development, agriculture, synthetic biology, and manufacturing.
Vilya Secures $71 Million Series A Funding Led by NVIDIA, ARCH, Madrona, and Menlo Ventures for AI-Driven Macrocyclic Drug Development
Vilya, a biotech startup developing macrocyclic drugs using AI and machine learning, announced an expanded $71 million Series A funding round led by ARCH Venture Partners, NVIDIA's NVentures, Madrona, and Menlo Ventures. The company, a spinout from Seattle's Institute for Protein Design, aims to revolutionize drug discovery with advanced protein engineering technologies.
University of Washington’s David Baker Credits Open-Code Rosetta Commons for Protein Design Startup Success
David Baker, director of the University of Washington’s Institute for Protein Design (IPD), emphasizes open code sharing as key to the institute’s success in creating protein design startups. The IPD’s collaborative Rosetta Commons consortium has enabled widespread development of protein design tools, fostering innovation and spinouts in biotech.
University of Washington’s CoMotion Spins Out Seven New Startups Including Biotech and 3D Printing Ventures Since July 2023
Since July last year, the University of Washington's CoMotion has spun out seven new startups focused on innovations from biotech to 3D printing. These are part of over 110 active UW spinouts collectively employing 1,000+ people and raising $4.1 billion in the past five years.
AstraZeneca to Acquire UW Spinout Icosavax for Up to $1.1 Billion to Boost Respiratory Vaccine Development
AstraZeneca announced it will acquire Seattle-based biotech spinout Icosavax, founded at the University of Washington, for up to $1.1 billion to accelerate development of vaccines targeting respiratory viruses. Icosavax's shares surged over 40% after the deal, which values the company at a 43% premium and aims to advance its lead RSV and hMPV vaccine candidate.
Seattle's Dexter Yard Develops into Major South Lake Union Biotech Cluster with Outpace Bio and Allen Institute
Seattle's Dexter Yard has become a growing biotech and life sciences hub, attracting companies like Outpace Bio and the Allen Institute with 528,000 square feet of new lab and office space. The area, located in South Lake Union, is part of a larger regional expansion of science facilities supported by major real estate developments and significant biotech investment.
Seattle Biotech Startup A-Alpha Bio Raises $22.4M to Advance AI Platform for Protein Interaction Analysis
Seattle biotech startup A-Alpha Bio raised $22.4 million to advance its AI-driven platform that measures protein interactions, partnering with major drug companies like Bristol Myers Squibb and Gilead Sciences to accelerate therapeutic development. Its platform combines computational tools and yeast experiments to analyze nearly 500 million protein-protein interaction measurements for drug discovery.
Hootsuite Names Jessica Hartigan CRO and Ellen Terchila CCO; EMOTIV, Institute for Protein Design, Appen, and Outreach Announce Executive Hires
Hootsuite appointed Jessica Hartigan as Chief Revenue Officer and Ellen Terchila as Chief Customer Officer, while other tech companies also announced key executive hires including Gary Flake at EMOTIV and Lynda Stuart at the Institute for Protein Design.
Neoleukin Therapeutics Cuts 70% of Workforce, CEO Jonathan Drachman to Step Down Amid Strategic Review
Neoleukin Therapeutics is cutting about 70% of its workforce and exploring strategic alternatives including sale or merger, with CEO Jonathan Drachman stepping down. The company’s stock rose by over 30% following the announcement.
University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs
University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.
Pacific Northwest Life Sciences Update: Talus Bioscience Raises $9.75M, Kineta Merges with Yumanity, UW’s David Baker Launches Charm Therapeutics
Recent Pacific Northwest life sciences news includes Talus Bioscience raising $9.75 million, Kineta going public via merger with Yumanity, and UW's David Baker launching Charm Therapeutics. Key partnerships involve TwinStrand and Singular Genomics developing rare gene variant tests, and Umoja Biopharma partnering with TreeFrog Therapeutics for stem cell therapies.
David Baker Launches London Biotech Charm Therapeutics with $50M Series A to Advance Deep Learning Drug Discovery
David Baker, leader of the University of Washington Institute for Protein Design, co-founded London-based Charm Therapeutics, which uses deep learning to discover new small molecule therapeutics, and recently secured $50 million in Series A funding. The company's DragonFold platform predicts protein-small molecule interactions to aid drug discovery in cancer and other diseases.
Five Finalists for 2022 GeekWire Health Innovation of the Year Include A-Alpha Bio and UW Institute for Protein Design
The 2022 GeekWire Health Innovation of the Year finalists include A-Alpha Bio, Parse Biosciences, Tasso, Truveta, and the University of Washington’s Institute for Protein Design, highlighting advances in computational health approaches. Winners will be announced on May 12 at the GeekWire Awards, with community voting open until April 22.
DoD awards $1.1M to Seattle’s A-Alpha Bio to hunt antibodies for COVID-19 variants with LLNL collaboration
Seattle biotech A-Alpha Bio received a $1.1 million DoD sub-contract to collaborate with Lawrence Livermore National Laboratory, using its AlphaSeq platform and machine learning to identify high-affinity antibodies against current and future COVID-19 variants.
People
-
Chris Picardo Board Observer
-
David Baker Director
